Cellipont Bioservices, a cell therapy contract development and manufacturing organization, announced plans to relocate from San Diego to The Woodlands in the first half of 2023.

According to a news release from The Woodlands Area Economic Development Partnership, Cellipont Bioservices will be developing a 76,000-square-foot facility in phases, with the first phase being scheduled to begin operation in the first half of 2023.

"Cellipont is excited to move forward with this next stage of our company’s development as a best-in-class cell therapy CDMO. As our client programs advance through the clinic and toward commercialization, we are working diligently to offer them state-of-the-art facilities and capabilities. This site near Houston is an ideal location to serve clients and patients across all of North America, with two major airports and a strong local workforce,” said Deborah Wild, chief executive officer at Cellipont Bioservices, in the release.

Ashley Byers, director of marketing and outreach for The Woodlands Area EDP, said the partnership facilitated the relocation.

“We are proud that Cellipont Bioservices will call The Woodlands home. Their dynamic facility will be a jewel among the growing bioscience companies in our Research Forest commercial area. With health care as our largest business sector, Cellipont will undoubtedly enhance the sustainability of our medical hub,” said Gil Staley, chief executive officer of The Woodlands Area EDP, in the release.

The new facility will be larger than Cellipont Bioservices' current 26,000-square-foot facility in San Diego. www.cellipont.com